论文部分内容阅读
[目的]观察以泰索帝为主的联合化疗治疗晚期妇科恶性肿瘤的疗效。[方法]泰索帝组51例晚期妇科恶性肿瘤患者,采用方案为泰索帝75mg/m2+顺铂60mg/m2+环磷酰胺600mg/m2。对照组为同期60例中晚期妇科恶性肿瘤患者,方案采用PAC(顺铂+环磷酰胺+表阿霉素)及VBP方案(长春新碱+平阳霉素+顺铂)。均化疗2￣6个周期。[结果]泰索帝组与对照组中位生存期分别为8.5个月和4个月(P<0.01),有效率(CR+PR)分别为43.1%与19.8%(P<0.05)。化疗毒副反应主要是骨髓抑制与脱发。[结论]以泰索帝为主的联合化疗治疗晚期妇科恶性肿瘤尤其是卵巢癌及输卵管癌近期疗效好,毒副反应较轻。
[Objective] To observe the efficacy of combination chemotherapy with Taxotere in the treatment of advanced gynecologic malignancies. [Method] 51 cases of advanced gynecological malignant tumor in Taxotere group were treated with Taxotere 75mg / m2 + cisplatin 60mg / m2 + cyclophosphamide 600mg / m2. The control group consisted of 60 patients with advanced gynecologic malignancies in the same period. The regimen consisted of PAC (cisplatin + cyclophosphamide + epirubicin) and VBP regimen (vincristine + pingyangmycin + cisplatin). All chemotherapy 2 ~ 6 cycles. [Results] The median survival time of Taxotere group and control group were 8.5 months and 4 months respectively (P <0.01). The effective rates (CR + PR) were 43.1% and 19.8% respectively (P <0.05). Chemotherapy toxicity mainly bone marrow suppression and hair loss. [Conclusion] The combination therapy of Taxotere predominantly has good curative effect and less toxic side effects in the treatment of advanced gynecological malignant tumor, especially ovarian cancer and fallopian tube cancer.